Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

Abstract Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse events (irAEs). Many of these are driven b...

Full description

Bibliographic Details
Main Authors: I. Puzanov, A. Diab, K. Abdallah, C. O. Bingham, C. Brogdon, R. Dadu, L. Hamad, S. Kim, M. E. Lacouture, N. R. LeBoeuf, D. Lenihan, C. Onofrei, V. Shannon, R. Sharma, A. W. Silk, D. Skondra, M. E. Suarez-Almazor, Y. Wang, K. Wiley, H. L. Kaufman, M. S. Ernstoff, on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group
Format: Article
Language:English
Published: BMJ Publishing Group 2017-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Immune-related adverse events
Toxicity
Immune checkpoint inhibitor
Online Access:http://link.springer.com/article/10.1186/s40425-017-0300-z

Internet

http://link.springer.com/article/10.1186/s40425-017-0300-z

Similar Items